Company Overview
Edwards Lifesciences is the global leader in patient-focused medical innovations for structural heart disease and critical care monitoring. Driven by a passion to help patients, the company collaborates with the world’s leading clinicians and researchers to address unmet healthcare needs, working to improve patient outcomes and enhance lives. Headquartered in Irvine, Calif., Edwards’ life saving innovations treat advanced cardiovascular disease and are sold in approximately 100 countries. Many of the company’s products are considered industry standards and over 95 percent of its sales are from products in leading positions. Edwards has extensive manufacturing operations in North America, Europe, Singapore and the Caribbean.

Patient-Focused Innovation Strategy
Focus  Singular focus on large unmet needs of structural heart and critically ill patients
Innovation  Pioneer breakthrough technologies with superior evidence
Leadership  Lead groundbreaking standards of care through trusted relationships

Poised for Long-Term Success
• Unwavering patient-focused culture motivates and guides our global team
• Differentiated strategy based on focus, innovation and leadership
• Credibility and trust with clinicians, regulators, payors and patients
• Transforming patient care drives growth and secures bright future

Quick Facts
Global Headquarters  Irvine, CA, USA
Worldwide Employees  15,000+
Website  edwards.com

Stock Information (as of September 30, 2021)
Stock Symbol  EW
Stock Exchange  NYSE
Stock Price  $113.21
Shares Outstanding  624.2 M
Market Capitalization  $70.7 B
Senior Management Ownership  Approximately 1%
Total Employee Ownership  Approximately 4%

Major Product Lines
Transcatheter Aortic Valve Replacement
In partnership with physicians worldwide, Edwards continues to lead the development of minimally invasive heart valve technologies enabling a streamlined procedure with excellent outcomes, rapid discharge and improved quality of life for patients with aortic stenosis. Through significant investment in technology advancement and clinical evidence, Edwards strives to further expand the treatment options for patients with aortic stenosis.

Transcatheter Mitral and Tricuspid Therapies
Edwards is making significant investments in the development of a differentiated portfolio of therapy options designed to treat mitral and tricuspid valve diseases.

Surgical Structural Heart
Edwards is committed to being the partner of choice for cardiac surgeons and helping transform patients’ lives by advancing surgical structural heart innovations. It is the world’s leading manufacturer of tissue heart valves and surgical heart valve repair therapies, which are used to treat a patient’s diseased heart valve.

Critical Care  Edwards is a world leader in hemodynamic monitoring systems used to measure a patient’s heart function and fluid status across care settings. Its complete hemodynamic portfolio helps clinicians make proactive clinical decisions and plays an important role in enhancing patient recovery.
Product Innovations

Transcatheter Aortic Valve Replacement  The proven SAPIEN 3 System is commercially available in over 75 countries and is now an approved treatment option for patients at low risk to surgery in the U.S., Europe, Japan and other countries around the world based on the superiority of outcomes demonstrated in PARTNER 3. The SAPIEN 3 Ultra system, (CE Mark and FDA approved) features advanced sealing skirt technology designed to reduce paravalvular leak, further elevating the performance of the SAPIEN 3 platform. The Edwards Pulmonic platform combines the SAPIEN 3 valve and the Alterra adaptive prosept to expand therapy for congenital heart disease patients. The next generation SAPIEN X4 system is in development. Studies of SAPIEN portfolio of TAVR devices in other patient populations are also continuing to enroll.

Transcatheter Mitral and Tricuspid Therapies  Edwards’ focused investment in structural heart initiatives has resulted in the development of multiple breakthrough therapies for patients suffering from mitral and tricuspid diseases:

- EVOQUE Eos (a) and SAPIEN M3 (a) transfemoral transcatheter mitral replacement systems are currently in clinical studies
- EVOQUE TR (a) transcatheter tricuspid replacement system is currently in clinical trial
- PASCAL(a) transcatheter valve repair system for mitral and tricuspid regurgitation received CE Mark in Europe, and is under clinical investigation in the U.S for both mitral and tricuspid regurgitation
- Cardioband(a) system is commercially available in Europe for transcatheter repair of the mitral and tricuspid valves

Surgical Structural Heart. The INSPIRIS RESILIA aortic valve is right for today, and ready for tomorrow. This valve features RESILIA tissue, a bovine pericardial tissue with advanced anti-calciification properties and proprietary VFit technology, which is designed for potential future valve-in-valve procedures. As the next offering in Edwards Lifesciences’ class of resilient RESILIA tissue valves, ready-to-implant KONECT RESILIA aortic valved conduit helps patients maintain their active lifestyles and reduces the complexity of bio-Bentall procedures. The HARPOON(a) system enables beating-heart mitral valve repair for patients with degenerative mitral regurgitation.

Critical Care  Edwards’ decision support solutions for clinicians include monitoring tools and noninvasive sensors. HemoSphere advanced monitoring platform, in combination with ForeSight Tissue Oximetry System, allows for a comprehensive view of tissue oximetry and advanced hemodynamics. The first-of-its-kind Acumen HPI software indicates the likelihood of a patient trending toward a low blood pressure event.